Clinical bottom line
Early intervention strategies combining immunotherapy with cognitive and behavioral approaches show promise in managing cognitive and behavioral symptoms in autoimmune encephalitis (AE). Intravenous immunoglobulin (IVIG) initiated promptly may improve cognitive deficits and neuropsychiatric manifestations, as suggested by recent case reports. Adjunctive cognitive behavioral therapy (CBT) techniques, adapted from developmental and adult frameworks, could support symptom management and functional recovery. However, high-quality controlled trials are lacking, and spontaneous remission can occur in some seronegative AE cases, complicating interpretation. Clinicians should consider early multidisciplinary intervention while recognizing the need for further evidence to define optimal timing, modalities, and patient selection.
What the evidence shows
Autoimmune encephalitis often presents with acute or subacute cognitive decline, memory impairment, and neuropsychiatric symptoms such as anxiety, depression, and behavioral disturbances (Samico et al., 2017). Immunotherapy, including corticosteroids, IVIG, and plasma exchange, remains the cornerstone of treatment. Naeem et al. (2023) reported a case of COVID-19-associated autoimmune encephalitis where early IVIG administration resulted in marked improvement in cognitive deficits and behavioral symptoms, highlighting the potential benefit of prompt immunomodulation.
Beyond immunotherapy, cognitive behavioral intervention strategies have been explored in related neuropsychiatric contexts. Developmental Cognitive Behavioral Therapy (CBT) frameworks emphasize tailored interventions addressing cognitive distortions and behavioral symptoms, which may be applicable to AE patients experiencing anxiety or depression (Developmental Cognitive Behavioral Therapy with Adults, 2013). Although direct evidence in AE is limited, CBT has demonstrated efficacy in reducing anxiety and depressive symptoms in adult populations (Ara Jesan et al., 2020; Cheung Ka-i et al., DOI:10.5353/th_b4072055), suggesting potential utility as an adjunctive therapy.
Najjar et al. (2011) described cases of spontaneously resolving seronegative autoimmune limbic encephalitis, indicating that some patients may improve without aggressive intervention. This underscores the heterogeneity of AE and the challenge in attributing clinical improvement solely to treatment modalities.
Caveats and uncertainty
The evidence base for early intervention strategies in AE is largely limited to case reports and small case series, lacking randomized controlled trials or large cohort studies. The heterogeneity of AE subtypes, antibody status, and clinical presentations complicates generalization. Spontaneous remission in some seronegative cases (Najjar et al., 2011) introduces uncertainty regarding the natural history versus treatment effect.
Furthermore, the application of CBT in AE is extrapolated from other neuropsychiatric disorders rather than directly studied in AE populations. The optimal timing, intensity, and modality of cognitive behavioral interventions remain undefined. Potential barriers include patients’ cognitive capacity during acute illness and access to specialized neuropsychological services.
How this may change practice
Clinicians managing AE should prioritize early diagnosis and initiation of immunotherapy, including IVIG, to potentially mitigate cognitive and behavioral sequelae. Incorporating neuropsychiatric assessment early in the disease course can identify candidates for adjunctive cognitive behavioral interventions.
Multidisciplinary collaboration involving neurologists, psychiatrists, and clinical psychologists may facilitate tailored cognitive behavioral strategies to address anxiety, depression, and behavioral symptoms, potentially improving quality of life and functional outcomes.
Given the current evidence limitations, clinicians should adopt a cautious, individualized approach and monitor patients closely for spontaneous improvement versus treatment response.